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Growth-differentiation factor 15 (GDF15) is an inflammatory cytokine involved in
energy homeostasis that is being pursued as a drug target for obesity. Its circulating
levels are acutely increased by the type 2 diabetes medication metformin, resulting in
reduced appetite and weight loss. We identified a genetic variant at the GDF15 gene
to proxy a small, lifelong increase in circulating GDF15 levels, and leveraged it in
colocalization and Mendelian randomization analyses to investigate the effects of
chronically elevated GDF15 levels on body mass index (BMI) and type 2 diabetes
liability. The results provide human genetic evidence supporting that chronically
elevated GDF15 levels increase BMI. There was no genetic evidence to support bi-
directional effects, or that chronically elevated GDF15 levels directly affect liability
to type 2 diabetes. Our results contrast the BMI-lowering effects of an acute increase
in GDF15 levels observed after metformin use. These findings have direct implica-
tions for informing pharmacological strategies aimed at targeting GDF15 levels for
weight loss.
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1 | INTRODUCTION
Growth-differentiation factor 15 (GDF15) is an inflammatory cytokine
involved in energy homeostasis that is being pursued as a drug target
for obesity.1 Its circulating levels are acutely increased by the type
2 diabetes medication metformin, resulting in reduced appetite and
weight loss.2 However, the effect of chronically elevated circulating
GDF15 levels on body weight is not known.
Here, we identified a genetic variant at the GDF15 gene to proxy
a small, lifelong increase in circulating GDF15 levels, and leveraged it
in genetic analyses to investigate the effects of chronically elevated
GDF15 levels on body mass index (BMI) and type 2 diabetes liability.
2 | METHODS
Colocalization and Mendelian randomization analyses were per-
formed. Briefly, colocalization compares the genetic associations for
two traits within a given genetic locus, investigating whether the data
support a model with a shared causal variant for both traits.3 In
Mendelian randomization, genetic variants that proxy the effect of
varying the exposure are used to investigate their effect on an out-
come.4 Our choice of genetic proxy for the effect of GDF15 signalling
was restricted to a variant at the GDF15 locus, to reduce the risk of
bias related to pleiotropic associations unrelated to GDF15.5 Further
details are provided in the Supporting Information.
Summary statistics data for the genetic associations of single-
nucleotide polymorphisms with each trait were obtained from publicly
available large-scale genome-wide association studies (GWAS) per-
formed on individuals of European ancestries. These data can be
obtained from the original studies, as detailed below. Genetic associa-
tions with circulating GDF15 levels were based on 3301 healthy
individuals,6 genetic associations with BMI were obtained from
a GWAS meta-analysis of 806 834 individuals,7 and genetic
associations with type 2 diabetes liability were based on a GWAS
meta-analysis of 74 124 cases and 824 006 controls.8 Relevant ethical
approval and participant consent were obtained by the original
studies.
3 | RESULTS
Colocalization analysis within the GDF15 gene supported the model
with a shared causal genetic variant (posterior probability > 0.99;
Figure 1) for GDF15 levels and BMI, with rs16982345 identified as
the most likely shared causal variant (P = 5.8 × 10−99 for the associa-
tion with GDF15 levels, and P = 4.4 × 10−9 for the association with
BMI). In Mendelian randomization analysis using the rs16982345
variant, genetically proxied higher circulating GDF15 levels were
associated with increased BMI (change in standard deviation
[SD] units per one SD increase in GDF15 levels: 0.021 [95% confi-
dence interval 0.014–0.028], P = 4.4 × 10−9). Exploring bi-directional
effects, there was no evidence of genetically proxied BMI being
associated with GDF15 levels (change in SD units per one SD increase
in BMI [95% confidence interval]: inverse-variance weighted estimate
0.005 [−0.133 to 0.143], P = .95; weighted median estimate: −0.059
[−0.260 to 0.143], P = .57; MR-Egger estimate −0.104 [−0.485 to
0.277], P = .59; MR-Egger intercept test for directional pleiotropy:
P = .55). There was no strong evidence for colocalization of GDF15
levels and type 2 diabetes liability (posterior probability = 0.16).
4 | DISCUSSION
Using human data, we provide genetic evidence supporting the notion
that chronically elevated GDF15 levels increase BMI. There was no
genetic evidence to support bi-directional effects, or that chronically
elevated GDF15 levels directly affect liability to type 2 diabetes. Our
results contrast with the BMI-lowering effects of an acute increase in
GDF15 levels observed after metformin use.2 There are a number of
possible explanations for this discrepancy, including that metformin
may be affecting BMI though mechanisms unrelated to GDF15. Long-
term elevation of circulating GDF15 levels may also contrast the
effects of acute increases in GDF15 and lead to desensitization of the
What is already known about this subject
• Growth-differentiation factor 15 is an inflammatory cyto-
kine involved in energy homeostasis that is being pursued
as a drug target for obesity.
• Circulating levels of growth-differentiation factor 15 are
acutely increased by the type 2 diabetes medication met-
formin, resulting in reduced appetite and weight loss.
• However, the effect of chronically elevated circulating
growth-differentiation factor 15 levels on body weight is
not known.
What this study adds
• Using human data, this study provides genetic evidence
supporting that chronically elevated circulating growth-
differentiation factor 15 levels increase body mass index.
• There was no genetic evidence to support bi-directional
effects, or that chronically elevated growth-differentiation
factor 15 levels directly affect liability to type 2 diabetes.
• These results contrast the BMI-lowering effects of an
acute increase in growth-differentiation factor 15 levels
observed after metformin use.
• These findings have direct implications for informing
pharmacological strategies aimed at targeting growth-
differentiation factor 15 levels for weight loss.
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GDF15 receptor and reduced signalling.9 Alternative possibilities
include compensatory changes in other hormones and behaviours
(including dietary intake) as a result of elevated circulating GDF15
levels. Furthermore, it is possible that GDF15 affects fetal and
childhood development, thus impacting adult BMI through this
mechanism.
The use of both colocalization and Mendelian randomization in
this study provide complementary evidence supporting causal effects
of chronically elevated GDF15 levels on BMI. As genetic variants are
randomly allocated at conception, the Mendelian randomization para-
digm is less susceptible to the confounding and reverse causation that
can hinder causal inference in observational studies. A previous
Mendelian randomization analysis exploring the effect of circulating
GDF15 levels on BMI used variants from throughout the genome in
their main analysis.10 While the greater number of variants generated
through this strategy allows for the incorporation of Mendelian ran-
domization statistical sensitivity analyses, this approach also risks
including variants that have pleiotropic associations unrelated to
GDF15, which can consequently bias the Mendelian randomization
analysis.5 Previous Mendelian randomization studies exploring the
effect of circulating GDF15 have also used GDF15 genetic association
estimates that were adjusted for systolic blood pressure, antihyper-
tensive medication use, diabetes mellitus and smoking status,10,11
which can introduce collider bias.12 Another previous study used a
genetic variant related to GDF15 gene expression in whole blood to
proxy the effect of varying GDF15 circulating levels.13 However,
colocalization analysis was not performed in this work, so it is unclear
whether genetic confounding was introducing bias into consequent
Mendelian randomization analysis.13 Such issues potentially explain
the discrepancy in the results of these previous studies with our
current work, which did not suffer from the same limitations.
As a limitation of our current work, the genetic associations were
derived from individuals of European ancestries, and therefore our
results may not generalize to other ethnic groups. A further limitation
is that we used BMI as a measure of obesity. However, BMI may also
be elevated in the context of increased lean mass and body water
content, and is not always reflective of increased body fat.
In conclusion, this genetic analysis found robust evidence to sup-
port that, in contrast to acute elevations in GDF15 levels, chronically
elevated GDF15 levels increase BMI. These findings may be used to
inform the design of pharmacological strategies aimed at targeting
GDF15 for weight loss.
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